NO931118L - Uracil reduktase inaktivatorer - Google Patents

Uracil reduktase inaktivatorer

Info

Publication number
NO931118L
NO931118L NO93931118A NO931118A NO931118L NO 931118 L NO931118 L NO 931118L NO 93931118 A NO93931118 A NO 93931118A NO 931118 A NO931118 A NO 931118A NO 931118 L NO931118 L NO 931118L
Authority
NO
Norway
Prior art keywords
halo
uracil reductase
uracil
inactivators
substd
Prior art date
Application number
NO93931118A
Other languages
English (en)
Other versions
NO931118D0 (no
NO313175B1 (no
Inventor
Thomas Spector
David John Timothy Porter
Saad George Rahim
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10682770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO931118(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO931118L publication Critical patent/NO931118L/no
Publication of NO931118D0 publication Critical patent/NO931118D0/no
Publication of NO313175B1 publication Critical patent/NO313175B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Vibration Dampers (AREA)
  • Springs (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Laminated Bodies (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transformer Cooling (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NO19931118A 1990-09-26 1993-03-25 Fremgangsmåte for fremstilling av en 5-fluoruracil farmasöytisk kombinasjon med forbedret stabilitet mot uracilreduktase NO313175B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909020930A GB9020930D0 (en) 1990-09-26 1990-09-26 Pharmaceutical combinations
PCT/GB1991/001650 WO1992004901A1 (en) 1990-09-26 1991-09-25 Uracil reductase inactivators

Publications (3)

Publication Number Publication Date
NO931118L true NO931118L (no) 1993-03-25
NO931118D0 NO931118D0 (no) 1993-03-25
NO313175B1 NO313175B1 (no) 2002-08-26

Family

ID=10682770

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19931118A NO313175B1 (no) 1990-09-26 1993-03-25 Fremgangsmåte for fremstilling av en 5-fluoruracil farmasöytisk kombinasjon med forbedret stabilitet mot uracilreduktase
NO980717A NO980717D0 (no) 1990-09-26 1998-02-20 Uracil reduktase inaktivatorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO980717A NO980717D0 (no) 1990-09-26 1998-02-20 Uracil reduktase inaktivatorer

Country Status (30)

Country Link
US (5) US6268374B1 (no)
EP (2) EP0550580B1 (no)
JP (2) JP2682739B2 (no)
KR (1) KR100222329B1 (no)
AT (1) ATE190489T1 (no)
BR (1) BR1100356A (no)
CA (2) CA2390654A1 (no)
CZ (4) CZ16196A3 (no)
DE (1) DE69132052T2 (no)
DK (1) DK0550580T3 (no)
ES (1) ES2143465T3 (no)
FI (1) FI112601B (no)
GB (1) GB9020930D0 (no)
GR (1) GR3033388T3 (no)
HK (1) HK1004188A1 (no)
HU (1) HU219589B (no)
IE (1) IE20010101A1 (no)
IL (2) IL99562A (no)
MC (1) MC2307A1 (no)
MY (1) MY128980A (no)
NO (2) NO313175B1 (no)
NZ (2) NZ239927A (no)
PT (1) PT99041B (no)
RU (1) RU2194511C2 (no)
SG (1) SG47912A1 (no)
SK (1) SK281894B6 (no)
TW (1) TW271397B (no)
UA (1) UA42679C2 (no)
WO (1) WO1992004901A1 (no)
ZA (1) ZA917667B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
WO1992020816A1 (en) * 1991-05-15 1992-11-26 Yale University Determination of prodrugs metabolizable by the liver and therapeutic use thereof
GB9322795D0 (en) * 1993-11-05 1993-12-22 Wellcome Found Novel compounds
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US7026301B2 (en) * 2002-10-17 2006-04-11 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
US20080255168A1 (en) * 2004-12-03 2008-10-16 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
KR20070098798A (ko) * 2004-12-03 2007-10-05 애드헤렉스 테크놀로지스 인크. Ｄｐｄ 억제제를 5-ｆｕ 및 5-ｆｕ 전구약물과 조합한투여방법
AU2012200856B2 (en) * 2004-12-03 2013-10-10 Adherex Technologies Inc. Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20090196833A1 (en) * 2008-02-06 2009-08-06 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
US8658618B2 (en) * 2009-10-14 2014-02-25 Adherex Technologies, Inc. Methods for preventing or reducing neurotoxicity associated with administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US10556872B2 (en) 2017-03-17 2020-02-11 Hampton University Fatty acid synthase inhibitors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324126A (en) * 1963-08-07 1967-06-06 Univ Kansas State Production of 5-trifluoromethyluracil
US4124765A (en) 1975-05-13 1978-11-07 Ono Pharmaceutical Co., Ltd. 5-Fluorouracil derivatives
DE2522369A1 (de) 1975-05-21 1976-12-02 Ono Pharmaceutical Co 5-fluoruracilderivate und verfahren zu ihrer herstellung
DD122381A1 (no) * 1975-10-03 1976-10-05
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
US4381344A (en) 1980-04-25 1983-04-26 Burroughs Wellcome Co. Process for producing deoxyribosides using bacterial phosphorylase
JPS6094971A (ja) * 1983-10-31 1985-05-28 Sagami Chem Res Center ５−ペルフルオロアルキルウラシル類の製造方法
US4719214A (en) 1985-07-25 1988-01-12 Southern Research Institute Carbocyclic analogues of thymine nucleosides
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
US4874602A (en) 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
CA1334535C (en) 1988-03-31 1995-02-21 Tadashi Miyasaka 6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof
US5077280A (en) 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US5198539A (en) * 1988-08-19 1993-03-30 Burroughs Wellcome Co. 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine
EP0566162B1 (en) * 1988-08-25 1997-06-11 Yoshitomi Pharmaceutical Industries, Ltd. 2'-Methylidenepyrimidine Nucleoside Compounds, their use and method for production thereof
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
EP0711555A2 (en) * 1990-07-19 1996-05-15 The Wellcome Foundation Limited Enzyme inactivators
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations

Also Published As

Publication number Publication date
UA42679C2 (uk) 2001-11-15
CZ50693A3 (en) 1994-02-16
JPH06504263A (ja) 1994-05-19
FI931337A (fi) 1993-03-25
US6268374B1 (en) 2001-07-31
ATE190489T1 (de) 2000-04-15
KR100222329B1 (en) 1999-10-01
US20070078106A1 (en) 2007-04-05
JP3003993B2 (ja) 2000-01-31
PT99041A (pt) 1992-08-31
NO980717D0 (no) 1998-02-20
US7704971B2 (en) 2010-04-27
CZ288515B6 (cs) 2001-07-11
DE69132052D1 (de) 2000-04-20
US20020042392A1 (en) 2002-04-11
GB9020930D0 (en) 1990-11-07
CZ16196A3 (en) 1996-05-15
SG47912A1 (en) 1998-04-17
IL99562A (en) 1999-11-30
DK0550580T3 (da) 2000-12-04
SK281894B6 (sk) 2001-09-11
US6297223B1 (en) 2001-10-02
CZ288520B6 (cs) 2001-07-11
AU654505B2 (en) 1994-11-10
FI931337A0 (fi) 1993-03-25
MC2307A1 (fr) 1993-09-27
PT99041B (pt) 1999-02-26
IE20010101A1 (en) 2002-03-20
TW271397B (no) 1996-03-01
GR3033388T3 (en) 2000-09-29
WO1992004901A1 (en) 1992-04-02
US7119096B2 (en) 2006-10-10
ZA917667B (en) 1993-03-25
FI112601B (fi) 2003-12-31
JP2682739B2 (ja) 1997-11-26
EP0550580B1 (en) 2000-03-15
SK23393A3 (en) 1993-07-07
NO980717L (no) 1993-03-25
IL121947A0 (en) 1998-03-10
NZ250799A (en) 1995-11-27
NZ239927A (en) 1995-11-27
IL99562A0 (en) 1992-08-18
HU9300863D0 (en) 1993-06-28
NO931118D0 (no) 1993-03-25
BR1100356A (pt) 2003-02-25
CZ170995A3 (en) 1995-12-13
MY128980A (en) 2007-03-30
CA2092435C (en) 2002-11-12
AU8540591A (en) 1992-04-15
HUT63765A (en) 1993-10-28
HU219589B (hu) 2001-05-28
JPH1045623A (ja) 1998-02-17
ES2143465T3 (es) 2000-05-16
CA2092435A1 (en) 1992-03-27
CA2390654A1 (en) 1992-04-02
EP0550580A1 (en) 1993-07-14
RU2194511C2 (ru) 2002-12-20
EP0985415A1 (en) 2000-03-15
HK1004188A1 (en) 1998-11-20
DE69132052T2 (de) 2000-08-03
US5817664A (en) 1998-10-06
CZ16296A3 (en) 1996-05-15
NO313175B1 (no) 2002-08-26

Similar Documents

Publication Publication Date Title
NO931118D0 (no) Uracil reduktase inaktivatorer
GR3026038T3 (en) Apparatus for respiration therapy.
GR3019508T3 (en) Derivatives of 2-aminopyrimidine-4-carboxamide, their preparation and therapeutic use
GB9010420D0 (en) New artist's easel
HU913814D0 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
GR3015716T3 (en) Use of buspirone in sleep apneas.
AP9200355A0 (en) "Therapeutic agent"
USD268976S (en) Portable orthopedic back rest
ITGE920048A1 (it) Ferratura d'arresto per parti spostabili di schienale o d'appoggio.
USD276300S (en) Cabinet door
MY111755A (en) Use of 4'-iodo-4'- deoxydoxorubicin for the treatment of amyloidosis.
Tingley Notes on the objectivity of meaning Gadamerian observations.
GR3022441T3 (en) Use of interleukine 10 to produce drugs with a tumour-inhibiting action
MX9701031A (es) Utilizacion de la selegilina para el tratamiento de enfermedades epilepticas.
AU115185S (en) Foresight Riser and barrel mount
ES1014286U (es) Armario blindado.
ES2050061A1 (es) Procedimiento de acoplamiento sobre placas de diferentes elementos.
IT1238896B (it) Apparecchio di tintoria e lavaggio per tessuti in corda, con parete regolabile per il controllo dell'affaldamento.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees